Once-daily asthma control, GSK’s Trelegy Ellipta expands its respiratory reach

GSK’s once-daily inhaler Trelegy Ellipta brings triple-therapy asthma control into a single device for adults whose symptoms remain uncontrolled on standard treatments, extending a product line that is already a mainstay in chronic obstructive pulmonary disease.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/15/2026 at 9:30 PM ET. Details in the imprint.

With its once-daily inhaler Trelegy Ellipta, GSK is pushing deeper into chronic respiratory care by offering a triple-therapy option for adults with asthma whose symptoms remain uncontrolled on standard dual therapies. The dry-powder inhaler combines an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta2-agonist in a single device, aiming to simplify regimens for patients who otherwise juggle multiple inhalers each day. The product, already well established for chronic obstructive pulmonary disease (COPD), has gained regulatory extensions over the past few years to cover certain adults with asthma whose disease remains inadequately controlled despite maintenance treatment.

What Trelegy Ellipta is designed to do for asthma patients

Trelegy Ellipta is a maintenance inhaler that delivers a fixed-dose combination of fluticasone furoate (an inhaled corticosteroid), umeclidinium (a long-acting muscarinic antagonist) and vilanterol (a long-acting beta2-agonist) via GSK’s Ellipta dry-powder platform, targeting persistent airway inflammation and bronchoconstriction in chronic respiratory disease. GSK positions the product for adults with asthma that is not adequately controlled on inhaled corticosteroid/long-acting beta2-agonist therapy, and for appropriate patients with moderate to very severe COPD, with the goal of providing once-daily dosing through a single inhaler rather than separate devices for each component; according to the company, the Ellipta device is designed to be activated in one step by opening the cover until a click is heard, after which the patient takes one inhalation. The official Trelegy patient site describes the device and triple-therapy components in detail.

In asthma, the idea behind triple therapy is to address multiple mechanisms driving symptoms and exacerbations: the inhaled steroid reduces airway inflammation, the muscarinic antagonist helps keep airways from tightening by blocking cholinergic pathways, and the beta2-agonist relaxes smooth muscle to improve airflow over a 24-hour period. Pivotal trials in adults whose asthma remained uncontrolled on dual therapy have shown that regimens like Trelegy’s fluticasone furoate/umeclidinium/vilanterol combination can improve lung function and reduce exacerbation rates versus certain dual-combination comparators, leading regulators in several major markets to add asthma indications on top of existing COPD approvals. In practical terms, clinicians may consider Trelegy Ellipta after stepping patients through guideline-based options and finding that symptoms or flare-ups remain problematic despite adherence to an inhaled corticosteroid/long-acting beta2-agonist inhaler.

From a usability standpoint, the Ellipta device incorporates a built-in dose counter and is preloaded with a month’s supply of individually sealed blisters, which open mechanically when the cover is lifted, eliminating the need to manually insert capsules or coordinate complex priming steps. For patients who struggle with multi-inhaler routines, that packaging and once-daily cadence are central selling points: instead of tracking separate inhalers for controller and bronchodilator medications, they take a single inhalation at about the same time each day, with healthcare professionals emphasizing correct inhalation technique and adherence at routine check-ups. The US prescribing information highlights that Trelegy Ellipta is not intended for relief of acute bronchospasm or as rescue therapy, and it must be used regularly even when the patient is asymptomatic.

GSK has invested heavily in respiratory medicines for decades, and Trelegy Ellipta sits alongside other Ellipta-branded inhalers such as Breo Ellipta (Relvar Ellipta outside the US) and Anoro Ellipta, giving the company a portfolio that spans different combinations and disease severities. Industry analyses and earnings disclosures have repeatedly identified Trelegy as a key growth driver in GSK’s respiratory business, particularly as older inhaler franchises lose exclusivity and face generic competition. To support broader clinical uptake, GSK has sponsored long-term studies and real-world evidence programs that look at exacerbation reduction, health-related quality of life metrics and healthcare utilization in patients switched from multi-inhaler regimens to single-inhaler triple therapy, data that are commonly cited in respiratory conferences and professional guidelines when clinicians consider escalation pathways.

Respiratory medicine is also a major focus area in GSK’s pipeline beyond Trelegy Ellipta, with internal candidates and external collaborations aimed at inflammatory pathways, biologics for severe asthma and emerging modalities such as antisense and siRNA approaches targeting upstream disease drivers. Against that backdrop, Trelegy’s asthma extension underscores how the company is trying to maintain a strong presence in both primary care and specialist respiratory settings while balancing investment between long-established inhaled therapies and newer, often higher-priced biologics. For payers and health systems, the presence of a once-daily single-inhaler triple option offers an additional tool in tailoring treatment based on severity, adherence concerns and cost-effectiveness analyses.

Respiratory products such as Trelegy Ellipta sit within a broader GSK portfolio that spans vaccines, specialty medicines and general pharmaceuticals, giving the group multiple revenue pillars at a time when competition around chronic disease treatments is intense. Recent market commentary has highlighted how investors are scrutinizing the company’s pipeline moves, including a planned acquisition of oncology-focused Nuvalent that would add several precision cancer assets to the R&D mix and diversify beyond traditional respiratory and infectious disease franchises. According to a Reuters report, GSK agreed this month to acquire Nuvalent for about $10.6 billion, its largest deal in more than a decade. Shares of GSK plc (ISIN GB0009252882) last traded on the London Stock Exchange around 1,983 pence on June 15, 2026, with UK market data providers such as AJ Bell showing an intraday move of roughly flat to slightly negative territory for the session. Recent LSE pricing and quote information for GSK is available via AJ Bell’s market-research page.

Trelegy Ellipta quick profile

• Product: Trelegy Ellipta
• Manufacturer: GSK plc
• Category: New Release/Launch - respiratory maintenance inhaler
• Launch date: Initial COPD approval 2017 (US); asthma indication added subsequently in adults with inadequately controlled disease in selected markets
• MSRP / Price: Price varies by market, insurer and pharmacy; Trelegy Ellipta is typically reimbursed as a branded prescription medicine rather than sold at a uniform list price
• Availability: Prescription-only in the US, UK and other major markets via retail and specialty pharmacies
• Target audience: Adults with asthma or COPD whose symptoms are not adequately controlled on dual maintenance therapy, as assessed by a healthcare professional
• Key differentiator / USP: Once-daily single-inhaler triple therapy combining an inhaled corticosteroid, long-acting muscarinic antagonist and long-acting beta2-agonist in GSK’s Ellipta device

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.